The Korean Journal of Urological Oncology10.22465/kjuo.2021.19.1.60202119160-69Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With EnzalutamideDong Hyeon An, Hwiwoo Kim, Donghyun Lee, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn,,
OncoTargets and Therapy10.2147/ott.s804882015871Enzalutamide for patients with metastatic castration-resistant prostate cancerWijdan Ramadan, Wissam Kabbara, Hiba Al Basiouni Al Masri
Annals of Oncology10.1016/j.annonc.2020.10.452202031S1332232P Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experienceR. Raju, A. Sahu, M. Klevansky, J. Torres,
Managing Metastatic Prostate Cancer In Your Urological Oncology Practice10.1007/978-3-319-31341-2_102016157-169Enzalutamide in Metastatic Castration Resistant Prostate CancerJeffrey Shevach, Bridget K. Marcellino, William K. Oh, Che-Kai Tsao
Drugs10.1007/s40265-013-0129-9201373151723-1732Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate CancerMark Sanford,,
Cancer Treatment and Research Communications10.1016/j.ctarc.2020.100205202025100205Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancerUmang Swami, Neeraj Agarwal,
Managing Metastatic Prostate Cancer In Your Urological Oncology Practice10.1007/978-3-319-31341-2_5201665-75Predictive Models in Castration Resistant Prostate CancerTao Cui, Michael W. Kattan
The Prostate10.1002/pros.239382019803247-255Higher serum testosterone levels predict poor prognosis in castrationā€resistant prostate cancer patients treated with docetaxelKeisuke Ando, Shinichi Sakamoto, Nobushige Takeshita, Ayumi Fujimoto, Maihulan Maimaiti, Shinpei Saito, Pae Sanjyon, Yusuke Imamura, Nobuo Sato, Akira Komiya, Koichiro Akakura, Tomohiko Ichikawa,,,
Prostate Cancer and Prostatic Diseases10.1038/s41391-020-0209-32020232220-231Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysisYupeng Guan, Haiyun Xiong, Yupeng Feng, Guolong Liao, Tongyu Tong, Jun Pang,,
Prostate Cancer and Prostatic Diseases10.1038/s41391-021-00318-32021Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetateScott T. Tagawa, Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, Daniel J. George,,